382 related articles for article (PubMed ID: 8998185)
21. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate.
Hara I; Miyake H; Yamada Y; Takechi Y; Hara S; Gotoh A; Fujisawa M; Okada H; Arakawa S; Soejima T; Sugimura K; Kamidono S
Int J Urol; 2002 Jun; 9(6):322-8; discussion 328. PubMed ID: 12269247
[TBL] [Abstract][Full Text] [Related]
22. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy in cT3 prostatic carcinoma: retrospective comparison between neoadjuvant and adjuvant hormonotherapy.
Cellini N; Luzi S; Morganti AG; Valentini V; Mantini G; Racioppi M; Smaniotto D; Leone M; Mattiucci GC; Digesù C; Giustacchini M; Destito A; Alcini E
Urol Int; 2004; 72(1):21-7. PubMed ID: 14730161
[TBL] [Abstract][Full Text] [Related]
24. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
D'Amico AV; Halabi S; Vollmer R; Loffredo M; McMahon E; Sanford B; Archer L; Vogelzang NJ; Small EJ; Kantoff PW;
Urology; 2008 May; 71(5):933-7. PubMed ID: 18291508
[TBL] [Abstract][Full Text] [Related]
25. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
26. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
Ray ME; Bae K; Hussain MH; Hanks GE; Shipley WU; Sandler HM
J Natl Cancer Inst; 2009 Feb; 101(4):228-36. PubMed ID: 19211454
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Bolla M
Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
[TBL] [Abstract][Full Text] [Related]
28. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
Shipley WU; Lu JD; Pilepich MV; Heydon K; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA; Machtay M
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1302-10. PubMed ID: 12459350
[TBL] [Abstract][Full Text] [Related]
29. Hormono-radiotherapy in prostatic carcinoma: prognostic factors and implications for combined modality treatment.
Cellini N; Luzi S; Morganti AG; Mantini G; Valentini V; Racioppi M; Leone M; Mattiucci GC; Di Gesù C; Giustacchini M; Destito A; Smaniotto D; Alcini E
Tumori; 2002; 88(6):495-9. PubMed ID: 12597145
[TBL] [Abstract][Full Text] [Related]
30. Tumor hypoxia, p53, and prognosis in cervical cancers.
Haensgen G; Krause U; Becker A; Stadler P; Lautenschlaeger C; Wohlrab W; Rath FW; Molls M; Dunst J
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):865-72. PubMed ID: 11429213
[TBL] [Abstract][Full Text] [Related]
31. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
32. A phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy alone for locally advanced prostate cancer. The Radiation Therapy Oncology Group.
Eur Urol; 1994; 26 Suppl 1():3. PubMed ID: 7737256
[No Abstract] [Full Text] [Related]
33. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
Pollack A; Grignon DJ; Heydon KH; Hammond EH; Lawton CA; Mesic JB; Fu KK; Porter AT; Abrams RA; Shipley WU
J Clin Oncol; 2003 Apr; 21(7):1238-48. PubMed ID: 12663710
[TBL] [Abstract][Full Text] [Related]
34. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
35. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
Shipley WU; Desilvio M; Pilepich MV; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1162-7. PubMed ID: 16427211
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.
Zhang M; Ho A; Hammond EH; Suzuki Y; Bermudez RS; Lee RJ; Pilepich M; Shipley WU; Sandler H; Khor LY; Pollack A; Chakravarti A
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1033-42. PubMed ID: 18977097
[TBL] [Abstract][Full Text] [Related]
39. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
40. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
Lawton CA; Winter K; Byhardt R; Sause WT; Hanks GE; Russell AH; Rotman M; Porter A; McGowan DG; DelRowe JD; Pilepich MV
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):931-9. PubMed ID: 9276357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
